Abstract
Thrombolytic (fibrinolytic) agents include alteplase (tissue plasminogen activator), anistreplase (anisoylated plasminogen streptokinase activator complex), reteplase, streptokinase, tenecteplase, and urokinase.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Haire WD. Pharmacology of fibrinolysis. Chest. 1992;101:91S–7S.
Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.
Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.
Smithson JE, Kennedy CT, Hughes S. A new skin lesion associated with intravenous streptokinase. BMJ. 1993;306:973.
Mirowska-Guzel D, Kobayashi A, Członkowska A. Widespread subcutaneous haematoma after thrombolytic therapy in stroke patients. Mild falls at stroke onset may be dangerous. Neurol Neurochir Pol. 2006;40:536–8.
Khanlou H, Malhotra G, Khanlou N, Eiger G, Frechie P. Massive subfascial hematoma after alteplase therapy for acute myocardial infarction. Am J Med Sci. 1999;317:53–4.
Cooper JP, Quarry DP, Beale DJ, Chappell AG. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J. 1994;70:592–3.
Cannas S, De Leo A, Marzari A. Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA). G Ital Cardiol. 1997;27:278–80.
Massel D, Gill JB, Cairns JA. Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction. Can J Cardiol. 1991;7:298–302.
Vidovich RR, Heiselman DE, Hudock D. Treatment of urokinase-related anaphylactoid reaction with intravenous famotidine. Ann Pharmacother. 1992;26:782–3.
Pechlaner C, Knapp E, Wiedermann CJ. Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. Blood Coagul Fibrinolysis. 2001;12:491–4.
Zarar A, Khan AA, Adil MM, Qureshi AI. Anaphylactic shock associated with intravenous thrombolytics. Am J Emerg Med. 2014;32:113.e3–5.
Ong AC, Handler CE, Walker JM. Hypersensitivity vasculitis complicating intravenous streptokinase therapy in acute myocardial infarction. Int J Cardiol. 1988;21:71–3.
Bucknall C, Darley C, Flax J, Vincent R, Chamberlain D. Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. Br Heart J. 1988;59:9–11.
Burrows N, Jones RR. Rash after treatment with anistreplase. Br Heart J. 1990;64:289–90.
Gupta S, Gupta S, Thomas M, Pandey P, Aggarwal M, Mahendra A, Jindal N. Streptokinase induced purpura-like lesions. Acta Med Indones. 2012;44:69–70.
Yerushalmi J, Zvulunov A, Halevy S. Serum sickness-like reactions. Cutis. 2002;69:395–7.
Al-Niaimi F. Drug eruptions in dermatology. Expert Rev Dermatol. 2011;6:273–86.
Schweitzer DH, van der Wall EE, Bosker HA, Scheffer E, Macfarlane JD. Serum-sickness-like illness as a complication after streptokinase therapy for acute myocardial infarction. Cardiology. 1991;78:68–71.
Creamer JD, McGrath JA, Webb-Peploe M, Smith NP. Serum sickness-like illness following streptokinase therapy. A case report. Clin Exp Dermatol. 1995;20:468–70.
Clesham GJ, Terry HJ, Jalihal S, Toghill PJ. Serum sickness and purpura following intravenous streptokinase. J R Soc Med. 1992;85:638–9.
Davies KA, Mathieson P, Winearls CG, Rees AJ, Walport MJ. Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction. Clin Exp Immunol. 1990;80:83–8.
Patel A, Prussick R, Buchanan WW, Sauder DN. Serum sickness-like illness and leukocytoclastic vasculitis after intravenous streptokinase. J Am Acad Dermatol. 1991;24:652–3.
Schwartz MW, McDonald GB. Cholesterol embolization syndrome. Occurrence after intravenous streptokinase therapy for myocardial infarction. JAMA. 1987;258:1934–5.
Bucher A, Roald B. Cholesterol embolization after intravenous streptokinase therapy in acute myocardial infarction. Tidsskr Nor Laegeforen. 1993;113:1844–5.
Arora RR, Magun AM, Grossman M, Katz J. Cholesterol embolization syndrome after intravenous tissue plasminogen activator for acute myocardial infarction. Am Heart J. 1993;126:225–8.
Pettelot G, Bracco J, Barrillon D, Baudouy M, Morand P. Images in cardiovascular medicine. Cholesterol embolization: unrecognized complication of thrombolysis. Circulation. 1998;97:1522.
Bhardwaj M, Goldweit R, Erlebacher J, Kashani M, Levin D, Leber G. Tissue plasminogen activator and cholesterol crystal embolization. Ann Intern Med. 1989;111:687–8.
Wong FK, Chan SK, Ing TS, Li CS. Acute renal failure after streptokinase therapy in a patient with acute myocardial infarction. Am J Kidney Dis. 1995;26:508–10.
Queen M, Biem HJ, Moe GW, Sugar L. Development of cholesterol embolization syndrome after intravenous streptokinase for acute myocardial infarction. Am J Cardiol. 1990;65:1042–3.
Dykewicz MS, McMorrow NK, Davison R, Fintel DJ, Zull CC, Rutledge JL. Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase). J Allergy Clin Immunol. 1995;95:1020–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag London
About this chapter
Cite this chapter
Özkaya, E., Yazganoğlu, K.D. (2014). Thrombolytics. In: Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer, London. https://doi.org/10.1007/978-1-4471-6536-1_13
Download citation
DOI: https://doi.org/10.1007/978-1-4471-6536-1_13
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-6535-4
Online ISBN: 978-1-4471-6536-1
eBook Packages: MedicineMedicine (R0)